Skip to main content
Premium Trial:

Request an Annual Quote

ABI Wraps Up $273M Acquisition of Ambion s RNA Business

NEW YORK, March 2 (GenomeWeb News) - Applied Biosystems has closed its acquisition of the research products division of Ambion.

 

The $273-million cash acquisition, which the firms announced in late December, enables ABI to enter the consumables market for sample prep, RNAi, microRNA, and gene-expression and array products.

 

The market in which this business plays is believed to be around $500 million market and grows more than 10 percent annually, according to ABI.

 

The research products division has about 300 employees, and will continue to be based in Austin. It will report to ABI's molecular biology division.

 

According to ABI, Ambion stands to generate more than $52 million in revenue in 2005, which would be a 22-percent improvement over last year's receipts.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.